Showing results (161-170 of 179) with videos related to

Sort By:
Pageof 18
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 2, 2013
PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancerFiona L Day, Robert N Jorissen, Lara Lipton, et al.
Lancet (London, England)|June 24, 2019
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trialWilliam D Tap, Hans Gelderblom, Emanuela Palmerini, et al.
Cancer Research|November 10, 2012
SMAD2, SMAD3 and SMAD4 mutations in colorectal cancerNicholas I Fleming, Robert N Jorissen, Dmitri Mouradov, et al.
JAMA Oncology|September 28, 2023
Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled TrialTae Won Kim, Philippe L Bedard, Patricia LoRusso, et al.
Science Translational Medicine|April 5, 2023
T<sub>STEM</sub>-like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical modelsDeborah Meyran, Joe Jiang Zhu, Jeanne Butler, et al.
The New England Journal of Medicine|August 23, 2023
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a <i>KRAS</i> G12C MutationAdrian Sacher, Patricia LoRusso, Manish R Patel, et al.
JCO Precision Oncology|February 9, 2022
Tumor-Infiltrating Lymphocyte Function Predicts Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal CancerJoseph Cherng Huei Kong, Glen Robert Guerra, Rosemary Magdalena Millen, et al.
JCO Precision Oncology|December 22, 2025
CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (<i>NRG1</i>) FusionsTejas Patil, Jessica J Lin, Parneet K Cheema, et al.
NPJ Precision Oncology|May 7, 2026
A roadmap for establishing institutional readiness for cellular therapies targeting solid tumours and autoimmune diseasesSarah Childs, David Ma, Elizabeth Houghton, et al.
The New England Journal of Medicine|October 1, 2019
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E-Mutated Colorectal CancerScott Kopetz, Axel Grothey, Rona Yaeger, et al.
Pageof 18